Have radiographic suspicion of newly diagnosed glioblastoma (GBM).
o If final pathology reports IDH mutant glioma, then the patients found to have an IDH mutation will be followed for safety and QoL measures but will not be included in the primary and secondary comparative survival and efficacy analyses.
Are medically and surgically appropriate for resection.
Have an estimated Karnofsky Performance Scale (KPS) score of ≥70.
Are able to receive standard of care treatment.
You may not be if
A previous biopsy diagnosis other than IDH wild-type GBM.
Have contraindications to TMZ, magnetic resonance imaging, gadolinium, or non-contrast computed tomography.
Have multi-focal enhancing tumors that cannot be encompassed in one operative field.
